Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
0.4788
-0.0198 (-3.97%)
At close: Mar 28, 2025, 4:00 PM
0.4772
-0.0016 (-0.33%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Polyrizon Employees
As of December 31, 2024, Polyrizon had 6 total employees, including 2 full-time and 4 part-time employees.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$267,500
Market Cap
2.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLRZ News
- 1 day ago - Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting - GlobeNewsWire
- 3 days ago - Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment - GlobeNewsWire
- 14 days ago - Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments - GlobeNewsWire
- 15 days ago - Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform - GlobeNewsWire
- 17 days ago - Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - GlobeNewsWire
- 18 days ago - Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform - GlobeNewsWire
- 2 months ago - Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform - GlobeNewsWire
- 2 months ago - Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - GlobeNewsWire